The role of AGEs and AGE inhibitors in diabetic cardiovascular disease.
about
Prevention of non-enzymatic glycosylation (glycation): Implication in the treatment of diabetic complicationTherapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathyRegenerative therapies for diabetic microangiopathyProtein carbonylation, cellular dysfunction, and disease progressionAdvanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy.Methylglyoxal mediates adipocyte proliferation by increasing phosphorylation of Akt1Relationship between Dietary Fat Intake, Its Major Food Sources and Assisted Reproduction ParametersIn vitro antidiabetic potential of the fruits of Crataegus pinnatifida.Tuning three-dimensional collagen matrix stiffness independently of collagen concentration modulates endothelial cell behaviorAnalysis of advanced glycation end products in the DHS Mind Study.Treatment with a copper-selective chelator causes substantive improvement in cardiac function of diabetic rats with left-ventricular impairmentAminoguanidine prevents the impairment of cardiac pumping mechanics in rats with streptozotocin and nicotinamide-induced type 2 diabetesThe metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat.The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetesPharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis.Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice.Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagenOxidative stress in diabetes and Alzheimer's disease.RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?Diabetes and Alzheimer's Disease: Can Elevated Free Copper Predict the Risk of the Disease?Molecular mechanisms of cardiomyocyte aging.Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.Molecular basis of arterial stiffening: role of glycation - a mini-review.The renal endothelium in diabetic nephropathy.Advanced glycation end-products: a common pathway in diabetes and age-related erectile dysfunction.AGEs and chronic subclinical inflammation in diabetes: disorders of immune system.The inhibitory activities of the edible green alga Capsosiphon fulvescens on rat lens aldose reductase and advanced glycation end products formation.Physiological and therapeutic effects of carnosine on cardiometabolic risk and disease.Glycative Stress and Its Defense Machinery Glyoxalase 1 in Renal Pathogenesis.Differential effects of dialysis and ultrafiltrate from individuals with CKD, with or without diabetes, on platelet phosphatidylserine externalization.Limited joint mobility in diabetes and ageing: recent advances in pathogenesis and therapy.In vitro and in vivo inhibitory activities of four Indian medicinal plant extracts and their major components on rat aldose reductase and generation of advanced glycation endproducts.Luteolin alleviates methylglyoxal-induced cytotoxicity in osteoblastic MC3T3-E1 cells.Effects of bergenin on methylglyoxal-induced damage in osteoblastic MC3T3-E1 cells.Bergenin increases osteogenic differentiation and prevents methylglyoxal-induced cytotoxicity in MC3T3-E1 osteoblasts.Quercetin inhibits advanced glycation end product formation via chelating metal ions, trapping methylglyoxal, and trapping reactive oxygen species.Effects of strontium fructose 1,6-diphosphate on expression of apoptosis-related genes and oxidative stress in testes of diabetic rats.Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis.Advanced glycation end-products accumulation compromises embryonic development and achievement of pregnancy by assisted reproductive technology.Dihydroxanthyletin-type coumarins from Angelica decursiva that inhibits the formation of advanced glycation end products and human recombinant aldose reductase.
P2860
Q26751110-A50ACF83-FD9C-4959-816A-18AF8DD8EDC0Q27021701-289BA5D2-2556-4950-9090-4899CF53F4CFQ27027852-3CB21F89-EEE8-4558-BD97-5EF289C70F7BQ28248107-CD292AE7-130A-40B1-AA8B-218264DCE464Q33691265-0223A794-8CC6-41B4-B9BB-6009EE420274Q34273637-346CECF6-909C-4478-AAAB-6F5FCF48D195Q34490729-4DF5D425-2608-472F-BBC2-A9F88D31EAECQ34931337-7E563EDC-9C03-4CAE-83E7-0B1C1E5834C9Q36428268-A366E4B1-0ED3-4025-9898-93AF786D1238Q36600193-ACD49834-1F93-4734-A8AC-57F574990019Q36698294-BF73F356-11AF-4235-8668-7585273BD393Q36736336-67BB571A-B632-4F31-9554-115EE6A9282EQ37158848-C3630D57-7EF2-46E9-B2C0-371FEF3434BAQ37236230-765B0664-8AF4-4CEE-982A-41B553CAC0A2Q37258222-F8E90A40-3D12-41CD-BC98-A3F11A58B3B8Q37370688-A0E8C8FF-664C-4D78-9039-C409E2E4948DQ37395276-D7A512A3-6B16-4597-A24D-ED16E417D2CDQ37455830-F3B33B4D-7124-4EEC-966C-7E1686F04569Q37455857-F9ABD3B7-E248-4298-B5A7-F859D18EEE02Q37635602-B82462F6-AD98-4794-A0FF-81E8BDFB79C1Q37893685-2A0F051D-E4DE-4DA1-ACAD-98958DF9D418Q37902643-D83A601A-38F9-4E97-B3AB-8D903638F577Q37973610-782169F4-A7BE-4897-87E4-539A68446335Q38087656-70C9AEB2-3293-47EF-9004-17F6EA06C014Q38118993-079445AD-AA8B-4193-928D-CF82F8815139Q38213275-9AFBC8B6-E65D-48BE-B66B-B6F7160029D5Q38451453-6EB48E73-1C17-4412-84DD-3D8559282749Q38777574-EF20A747-1CD6-47DC-AA25-176FB51E2EE4Q39096507-BE9A2FBC-EA57-4228-9E8D-0B4CE644115CQ42516903-DFD189E1-99B3-4235-9290-31141236E033Q42756908-E4715E9B-ED78-4A79-9410-B47650B08ABDQ43466937-612F63D6-7931-4372-9E02-02C50ECA75E5Q44691601-4D73E981-9A31-47CE-92F9-826A7EF05EFAQ46259674-F6507747-DA3E-440C-A6DA-1F9E6DD73E49Q46308563-514BAA0C-B595-412F-BA65-4FA8B89B2215Q46388088-3E12F2B6-298C-411B-8AA2-54F8C52813FDQ46730659-BF76819D-3485-4E8D-8294-54AF05CED57AQ47346953-CB5DB778-DB2D-4F06-B772-567D7DE96156Q48683430-C90D4D83-7B75-4DC3-BAE8-A008179C2763Q49913426-35B2AA1A-6A1F-40F7-BA7A-2F3ABAD0E267
P2860
The role of AGEs and AGE inhibitors in diabetic cardiovascular disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The role of AGEs and AGE inhibitors in diabetic cardiovascular disease.
@ast
The role of AGEs and AGE inhibitors in diabetic cardiovascular disease.
@en
type
label
The role of AGEs and AGE inhibitors in diabetic cardiovascular disease.
@ast
The role of AGEs and AGE inhibitors in diabetic cardiovascular disease.
@en
prefLabel
The role of AGEs and AGE inhibitors in diabetic cardiovascular disease.
@ast
The role of AGEs and AGE inhibitors in diabetic cardiovascular disease.
@en
P2093
P356
P1433
P1476
The role of AGEs and AGE inhibitors in diabetic cardiovascular disease
@en
P2093
J W Baynes
M E Cooper
S R Thorpe
P304
P356
10.2174/1389450054021873
P577
2005-06-01T00:00:00Z